Highlights Allarity Therapeutics, Inc.

Equities

ALLR

US0167444019

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
0.208 ^USD	-34.80%		-52.87%	-98.11%

06-25	Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer	CI
05-24	Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer	06-25	CI
Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial	05-24	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule	05-06	MT
Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib	05-02	CI
Top Premarket Gainers	04-12	MT
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	03-27	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-08	CI
Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic	12-05	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology	23-09-14	CI
Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic for Dovitinib in the Peer-Reviewed Journal PLOS ONE	23-08-30	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol? with DRP® Companion Diagnostics	23-07-31	CI
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol with DRP Companion Diagnostics	23-07-31	CI
Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of IxempraÂ®? in Metastatic Breast Cancer Patients	23-07-05	CI
Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study	23-05-30	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Allarity Therapeutics, Inc. Accelerates Trial Enrollment to Bring Fda-Approves Breast Cancer Treatment to European Market - Interim Results Could Be Released in Second Half of 2023	23-04-27	CI
Allarity Therapeutics Doses Its First Patient in Phase 1B of Its Clinical Trial for the Novel Combination Therapy of Two Drugs, Stenoparib and Dovitinib	23-04-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Allarity Therapeutics, Inc.

Equities

ALLR

US0167444019

Highlights

Filters